Bronchial Leiomyoma Market Research Report – Global Forecast till 2027

Bronchial Leiomyoma Market Research Report: By Site (Bronchi, Trachea), Diagnosis (Imaging, Blood Sampling, Biopsy), Treatment (Surgery, Bronchoscopy), End User (Hospitals & Clinics, Academic Institutes, Research Organization) - Global Forecast till 2027

ID: MRFR/Pharma/3418-HCR | | Region: Global | 90 pages

Market Scenario:


A bronchial leiomyoma is a rare form of lung tumor, which affects the lower respiratory tract tissues including bronchi, trachea, and other lung tissues. Bronchial leiomyoma constitutes approximately 33%-45% of respiratory system leiomyoma. Mostly, bronchial leiomyoma arises from the smooth muscle tissue lining of the bronchi and grow as solitary tumors being attached to the sides of the bronchi.  With the increasing prevalence of the lung cancer, the cases of the bronchial leiomyoma are estimated to increase, which is likely to drive the market growth during the forecast period 2017-2023.  In 2017, according to the American Cancer Society, about 222,500 new cases of lung cancer are reported leading to 155,870 deaths. Moreover, increasing per capita healthcare expenditure, developing healthcare sector are expected to boost the market growth during the forecasted period. In 2015, according to the Centres for Disease Control and Prevention, in the U.S. the total healthcare expenditure accounted for 17.8% of the total gross domestic product (GDP), which accounted for USD 3.2 trillion. Moreover, the per capita healthcare expenditure of the U.S. was about USD 9,990 within the same year. However, the complexity of diagnosis and treatment along with the lack of awareness of the disease may restrain the market growth during the forecast period. 


The global bronchial leiomyoma market is expected to grow at an approximate CAGR of 5.9% during the forecast period.


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


 


Figure 1:- Global bronchial leiomyoma market share, by region
Bronchial Leiomyoma Market


Sources: WHO, annual reports, press release, white paper, and company presentation 


Segmentation


The global bronchial leiomyoma market is segmented on the basis of the site, diagnosis, treatment, and end users.


On the basis of the site, the market is segmented into bronchi, trachea, and others.


On the basis of the diagnosis, the market is segmented into imaging, blood sampling, biopsy, and others. The imaging segment is sub-segmented into X-rays, CT scan, PET scan, and others. The blood sampling segment is sub-segmented into liver function test, thyroid profiling, renal function test, and others. 


On the basis of the treatment, the market is segmented into surgery, bronchoscopy, and others.


On the basis of the end users, the market is segmented into hospitals & clinics, academic institutes, research organization, and others. 


Regional Analysis


The Americas dominate the global bronchial leiomyoma market owing to a well-developed healthcare sector. Additionally, increasing number of patients, increasing healthcare expenditure have boosted the growth of the Americas market. Moreover, the presence of the global players like Eli Lilly and Company., Pfizer Inc., and GlaxoSmithKline Plc. and developed economies like the U.S. and Canada within the region fuel the market growth.


Europe is the second largest bronchial leiomyoma market, which is followed by Asia Pacific. Availability of funds for research, huge patient population, and government support for research & development drive the European market.


Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population and continuously developing economies like India and China. Moreover, the untapped market of the region has huge opportunities for the market growth.


On the other hand, the Middle East & Africa owns the least share of the global bronchial leiomyoma market due to the presence of poor economy, especially, in the African region, which has low per capita income. Moreover, stringent government policies may restrain the growth of the market in the African region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. 


Research Methodology

Global bronchial leiomyoma market


Sources: WHO, annual reports, press release, white paper, and company presentation 


 


Key players in the global bronchial leiomyoma market:
Hoffmann-La Roche Ltd (Europe), AstraZeneca (Europe), Eli Lilly and Company. (U.S.), Sanofi (Europe), Pfizer Inc. (U.S.), GlaxoSmithKline Plc. (U.S.), ArQule. (U.S.), Boehringer Ingelheim GmbH (Europe), and others.


 



Frequently Asked Questions (FAQ) :


bronchial leiomyoma market is projected to grow at approximately 5.9% CAGR during the assessment period (2020-2027).

Increasing per capita healthcare expenditure and developing healthcare sector are major tailwinds pushing the growth of the global bronchial leiomyoma market.

Complexity of diagnosis & treatment and the lack of awareness regarding the disease are major growth impeders for the global bronchial leiomyoma market.

North America holds the largest share in the global bronchial leiomyoma market, followed by Europe and the Asia Pacific, respectively.

Hoffmann-La Roche Ltd (Europe), Eli Lilly and Company. (U.S.), AstraZeneca (Europe), Sanofi (Europe), Pfizer Inc. (U.S.), ArQule. (U.S.), GlaxoSmithKline Plc. (U.S.), and Boehringer Ingelheim GmbH (Europe), are some of the top players operating in the global bronchial leiomyoma market.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Bronchial Leiomyoma Market, by Site

6.1 Introduction

6.2 Bronchi

Market Estimates & Forecast, 2020 – 2027

6.3 Trachea

Market Estimates & Forecast, 2020 – 2027

6.4 Others

Chapter 7. Global Bronchial Leiomyoma Market, by Diagnosis

7.1 Introduction

7.2 Imaging

Market Estimates & Forecast, 2020 – 2027

7.2.1 X Rays

7.2.2 CT Scan

7.2.3 PET Scan

7.2.4 Others

7.3 Blood Sampling

Market Estimates & Forecast, 2020 – 2027

7.3.1 Liver function Test

7.3.2 Thyroid Profiling

7.3.3 Renal Function Test

7.3.4 Others

7.4 Biopsy

Market Estimates & Forecast, 2020 – 2027

7.5 Others

Chapter 8. Global Bronchial Leiomyoma Market, by Treatment

8.1 Introduction

8.2 Surgery

Market Estimates & Forecast, 2020 – 2027

8.3 Bronchoscopy

Market Estimates & Forecast, 2020 – 2027

8.4 Others

Chapter 9 Global Bronchial Leiomyoma Market, by End Users

9.1 Introduction

9.2 Hospitals & Clinics

Market Estimates & Forecast, 2020 – 2027

9.3 Academic Institutes

Market Estimates & Forecast, 2020 – 2027

9.4 Research Organizations

Market Estimates & Forecast, 2020 – 2027

9.5 Others

Chapter 10. Global Bronchial Leiomyoma Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 US

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 F. Hoffmann-La Roche Ltd

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 AstraZeneca

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Eli Lilly and Company.

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Sanofi

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Pfizer Inc.

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 GlaxoSmithKline plc.

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 ArQule.

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Boehringer Ingelheim GmbH

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of cancer industry

Chapter 14 Appendix

LIST OF TABLES

Table 1 Bronchial Leiomyoma Industry Synopsis, 2020 – 2027

Table 2 Global Bronchial Leiomyoma Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Bronchial Leiomyoma Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Bronchial Leiomyoma Market by Site, 2020 – 2027, (USD Million)

Table 5 Global Bronchial Leiomyoma Market by Diagnosis, 2020 – 2027, (USD Million)

Table 6 Global Bronchial Leiomyoma Market by Treatment, 2020 – 2027, (USD Million)

Table 7 Global Bronchial Leiomyoma Market by End Users, 2020 – 2027, (USD Million)

Table 8 North America Bronchial Leiomyoma Market by Site, 2020 – 2027, (USD Million)

Table 9 North America Bronchial Leiomyoma Market by Diagnosis, 2020 – 2027, (USD Million)

Table 10 North America Bronchial Leiomyoma Market by Treatment, 2020 – 2027, (USD Million)

Table 11 North America Bronchial Leiomyoma Market by End Users, 2020 – 2027, (USD Million)

Table 12 US Bronchial Leiomyoma Market by Site, 2020 – 2027, (USD Million)

Table 13 US Bronchial Leiomyoma Market by Diagnosis, 2020 – 2027, (USD Million)

Table 14 US Bronchial Leiomyoma Market by Treatment, 2020 – 2027, (USD Million)

Table 15 US Bronchial Leiomyoma Market by End Users, 2020 – 2027, (USD Million)

Table 16 Canada Bronchial Leiomyoma Market by Site, 2020 – 2027, (USD Million)

Table 17 Canada Bronchial Leiomyoma Market by Diagnosis, 2020 – 2027, (USD Million)

Table 18 Canada Bronchial Leiomyoma Market by Treatment, 2020 – 2027, (USD Million)

Table 19 Canada Bronchial Leiomyoma Market by End Users, 2020 – 2027, (USD Million)

Table 20 South America Bronchial Leiomyoma Market by Site, 2020 – 2027, (USD Million)

Table 21 South America Bronchial Leiomyoma Market by Diagnosis, 2020 – 2027, (USD Million)

Table 22 South America Bronchial Leiomyoma Market by Treatment, 2020 – 2027, (USD Million)

Table 23 South America Bronchial Leiomyoma Market by End Users, 2020 – 2027, (USD Million)

Table 24 Europe Bronchial Leiomyoma Market by Site, 2020 – 2027, (USD Million)

Table 25 Europe Bronchial Leiomyoma Market by Diagnosis, 2020 – 2027, (USD Million)

Table 26 Europe Bronchial Leiomyoma Market by Treatment, 2020 – 2027, (USD Million)

Table 27 Europe Bronchial Leiomyoma Market by End Users, 2020 – 2027, (USD Million)

Table 28 Western Europe Bronchial Leiomyoma Market by Site, 2020 – 2027, (USD Million)

Table 29 Western Europe Bronchial Leiomyoma Market by Diagnosis, 2020 – 2027, (USD Million)

Table 30 Western Europe Bronchial Leiomyoma Market by Treatment, 2020 – 2027, (USD Million)

Table 31 Western Europe Bronchial Leiomyoma Market by End Users, 2020 – 2027, (USD Million)

Table 32 Eastern Europe Bronchial Leiomyoma Market by Site, 2020 – 2027, (USD Million)

Table 33 Eastern Europe Bronchial Leiomyoma Market by Diagnosis, 2020 – 2027, (USD Million)

Table 34 Eastern Europe Bronchial Leiomyoma Market by Treatment, 2020 – 2027, (USD Million)

Table 35 Eastern Europe Bronchial Leiomyoma Market by End Users, 2020 – 2027, (USD Million)

Table 36 Asia Pacific Bronchial Leiomyoma Market by Site, 2020 – 2027, (USD Million)

Table 37 Asia Pacific Bronchial Leiomyoma Market by Diagnosis, 2020 – 2027, (USD Million)

Table 38 Asia Pacific Bronchial Leiomyoma Market by Treatment, 2020 – 2027, (USD Million)

Table 39 Asia Pacific Bronchial Leiomyoma Market by End Users, 2020 – 2027, (USD Million)

Table 40 Middle East & Africa Bronchial Leiomyoma Market by Site, 2020 – 2027, (USD Million)

Table 41 Middle East & Africa Bronchial Leiomyoma Market by Diagnosis, 2020 – 2027, (USD Million)

Table 42 Middle East & Africa Bronchial Leiomyoma Market by Treatment, 2020 – 2027, (USD Million)

Table 43 Middle East & Africa Bronchial Leiomyoma Market by End Users, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Bronchial Leiomyoma Market

Figure 3 Segmentation Market Dynamics for Global Bronchial Leiomyoma Market

Figure 4 Global Bronchial Leiomyoma Market Share, by Site 2020

Figure 5 Global Bronchial Leiomyoma Market Share, by Diagnosis 2020

Figure 6 Global Bronchial Leiomyoma Market Share, by Treatment 2020

Figure 7 Global Bronchial Leiomyoma Market Share, by End Users, 2020

Figure 8 Global Bronchial Leiomyoma Market Share, by Region, 2020

Figure 9 North America Bronchial Leiomyoma Market Share, by Country, 2020

Figure 10 Europe Bronchial Leiomyoma Market Share, by Country, 2020

Figure 11 Asia Pacific Bronchial Leiomyoma Market Share, by Country, 2020

Figure 12 Middle East & Africa Bronchial Leiomyoma Market Share, by Country, 2020

Figure 13 Global Bronchial Leiomyoma Market: Company Share Analysis, 2020 (%)

Figure 14 F. Hoffmann-La Roche Ltd: Key Financials

Figure 15 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 16 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 17 AstraZeneca: Key Financials

Figure 18 AstraZeneca: Segmental Revenue

Figure 19 AstraZeneca: Geographical Revenue

Figure 20 Eli Lilly and Company: Key Financials

Figure 21 Eli Lilly and Company: Segmental Revenue

Figure 22 Eli Lilly and Company: Geographical Revenue

Figure 23 Sanofi: Key Financials

Figure 24 Sanofi: Segmental Revenue

Figure 25 Sanofi: Geographical Revenue

Figure 26 Pfizer Inc.: Key Financials

Figure 27 Pfizer Inc.: Segmental Revenue

Figure 28 Pfizer Inc.: Geographical Revenue

Figure 29 GlaxoSmithKline plc.: Key Financials

Figure 30 GlaxoSmithKline plc.: Segmental Revenue

Figure 31 GlaxoSmithKline plc.: Geographical Revenue

Figure 32 ArQule.: Key Financials

Figure 33 ArQule.: Segmental Revenue

Figure 34 ArQule.: Geographical Revenue

Figure 35 Boehringer Ingelheim GmbH: Key Financials

Figure 36 Boehringer Ingelheim GmbH: Segmental Revenue

Figure 37 Boehringer Ingelheim GmbH: Geographical Revenue